Navigating SG&A Expenses: AstraZeneca PLC vs. Zoetis Inc.

In the ever-evolving landscape of pharmaceuticals, effective cost management is crucial. Over the past decade, AstraZeneca PLC and Zoetis Inc. have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have seen a notable increase of approximately 35%, peaking in 2022. This reflects their aggressive expansion and marketing strategies. In contrast, Zoetis Inc. has maintained a more stable trajectory, with a modest 31% rise over the same period, indicating a more conservative approach.

Key Insights

• AstraZeneca's Growth: The company's SG&A expenses surged by 84% from 2016 to 2022, highlighting their investment in market penetration.
• Zoetis' Stability: Despite a steady increase, Zoetis' expenses remained under 12% of AstraZeneca's, showcasing efficient cost management.

Understanding these trends offers valuable insights into the financial strategies of leading pharmaceutical giants.